UnicoCell Biomed Co., Ltd. (TPE:6794)
65.50
+0.10 (0.15%)
May 9, 2025, 1:15 PM CST
UnicoCell Biomed Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2019 |
Net Income | -93.07 | -84.11 | -91.16 | -86.37 | -109.21 | Upgrade
|
Depreciation & Amortization | 27.25 | 26.18 | 24.09 | 25.53 | 22.88 | Upgrade
|
Other Amortization | 0.33 | 0.21 | 0.18 | 0.74 | 0.78 | Upgrade
|
Loss (Gain) From Sale of Assets | - | -4.83 | - | - | - | Upgrade
|
Loss (Gain) From Sale of Investments | 1.79 | - | - | - | - | Upgrade
|
Stock-Based Compensation | 1.39 | 1.82 | 2.96 | 2.26 | 3.05 | Upgrade
|
Provision & Write-off of Bad Debts | 0 | 0 | - | - | - | Upgrade
|
Other Operating Activities | -1.25 | -3.42 | -0.07 | 0.29 | -0.3 | Upgrade
|
Change in Accounts Receivable | -0.73 | -0.7 | -0.98 | 0.36 | 0.17 | Upgrade
|
Change in Inventory | -2.33 | 0.72 | -0.07 | -2.1 | 0.05 | Upgrade
|
Change in Accounts Payable | 1.87 | -0.81 | 0.84 | -0.4 | -1.92 | Upgrade
|
Change in Unearned Revenue | 6.6 | -1.51 | 1.52 | - | - | Upgrade
|
Change in Other Net Operating Assets | -3.36 | 0.9 | -0.92 | -2.02 | -7.66 | Upgrade
|
Operating Cash Flow | -61.52 | -65.55 | -63.6 | -61.71 | -92.16 | Upgrade
|
Capital Expenditures | -5.32 | -15.8 | -14.45 | -23.64 | -56.69 | Upgrade
|
Sale of Property, Plant & Equipment | - | 6.16 | - | - | - | Upgrade
|
Sale (Purchase) of Intangibles | -0.38 | -0.18 | -0.16 | -0.36 | -0.16 | Upgrade
|
Investment in Securities | -117.35 | -297.14 | -150.08 | -0.08 | - | Upgrade
|
Other Investing Activities | 0.71 | -0.24 | -0.3 | 0.27 | -0.27 | Upgrade
|
Investing Cash Flow | -122.35 | -307.2 | -164.99 | -23.8 | -57.12 | Upgrade
|
Long-Term Debt Repaid | -6.09 | -6.04 | -7.82 | -9.37 | -9.81 | Upgrade
|
Net Debt Issued (Repaid) | -6.09 | -6.04 | -7.82 | -9.37 | -9.81 | Upgrade
|
Issuance of Common Stock | 179.85 | 344.88 | 159.04 | 3.71 | 155.25 | Upgrade
|
Other Financing Activities | -0.22 | 0.17 | 0.15 | - | - | Upgrade
|
Financing Cash Flow | 173.54 | 339.01 | 151.38 | -5.66 | 145.44 | Upgrade
|
Net Cash Flow | -10.33 | -33.74 | -77.21 | -91.17 | -3.84 | Upgrade
|
Free Cash Flow | -66.84 | -81.35 | -78.05 | -85.34 | -148.85 | Upgrade
|
Free Cash Flow Margin | -209.66% | -330.82% | -542.15% | -1043.70% | -3737.95% | Upgrade
|
Free Cash Flow Per Share | -1.17 | -1.51 | -1.88 | -2.27 | -4.19 | Upgrade
|
Cash Interest Paid | 1.46 | 1.45 | 1.26 | 0.66 | 0.94 | Upgrade
|
Cash Income Tax Paid | 0.72 | 0.24 | 0.02 | 0.04 | 0.03 | Upgrade
|
Levered Free Cash Flow | -44.47 | -54.17 | -49.26 | -54.15 | -108.39 | Upgrade
|
Unlevered Free Cash Flow | -43.56 | -53.27 | -48.47 | -53.74 | -107.8 | Upgrade
|
Change in Net Working Capital | 2.49 | 5.31 | 3.53 | 3.69 | 8.06 | Upgrade
|
Updated Mar 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.